Raymond James Financial’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
Other funds holding PBE
Raymond James Financial's PBE Position: Q3 2026 in Review
Raymond James Financial increased its Invesco Biotechnology & Genome ETF (PBE) stake by 792% in Q3 2026, buying an estimated $7.5M and bringing the position to 89,960 shares worth $8.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2269.
Raymond James Financial first reported a position in PBE in Q4 2024 and has held it in 8 quarters since. 123 funds tracked by Wall St. Rank hold PBE as of Q3 2026.
- Raymond James Financial held 89,960 shares of Invesco Biotechnology & Genome ETF worth $8.75M as of Q3 2026.
- Raymond James Financial bought 79,870 Invesco Biotechnology & Genome ETF shares in Q3 2026, an estimated $7.5M.
- Invesco Biotechnology & Genome ETF made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #2269 holding.
- Raymond James Financial first reported a position in Invesco Biotechnology & Genome ETF in Q4 2024 and has held it in 8 quarters since.
- 123 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.
Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.